Replies to post #154708 on Biotech Values

[DewDiligence]

I owned XOMA in 2010 and took a 16k loss on 150k share position. What has changed since then?

New management and progress/expansion of the Gevokizumab program in uveitis (#msg-80192133).

[DonShimoda]

I also recently started a position in XOMA (although at slightly higher prices than Dew, lol). My understanding is that a lot has changed in the past year. First, they've got a solid partnership with Servier in place. Second, they've got a new CEO that has the company clearly focused on commercializing their lead candidate. They've also initiated a targeted P2 PoC program focused on orphan indications while retaining upside in the CV opportunity. I've done a lot of dd that I'd be more than happy to share with the board. I plan on making a series of posts over the next week or so that will hopefully form the basis for an RMF on the company.